Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · October 04, 2022

Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Alone vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Lancet 2022 Sep 09;[EPub Ahead of Print], E Livingstone, L Zimmer, JC Hassel, M Fluck, TK Eigentler, C Loquai, S Haferkamp, R Gutzmer, F Meier, P Mohr, A Hauschild, B Schilling, C Menzer, F Kiecker, E Dippel, A Roesch, M Ziemer, B Conrad, S Körner, C Windemuth-Kieselbach, L Schwarz, C Garbe, JC Becker, D Schadendorf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading